Relative Bioavailability of HTL0018318 Oral Aqueous Solution Versus Capsules
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
HTL0018318 is a selective muscarinc M1 agonist. This study is a phase I, open label,
randomised, crossover, single dose, trial in healthy volunteers to compare the relative
bioavailability of HTL0018318 when given by oral aqueous solution and in capsule formulation.